HK1107763A1 - Crth2 receptor ligands for medicinal uses - Google Patents
Crth2 receptor ligands for medicinal usesInfo
- Publication number
- HK1107763A1 HK1107763A1 HK07113481.2A HK07113481A HK1107763A1 HK 1107763 A1 HK1107763 A1 HK 1107763A1 HK 07113481 A HK07113481 A HK 07113481A HK 1107763 A1 HK1107763 A1 HK 1107763A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- receptor ligands
- crth2 receptor
- medicinal uses
- medicinal
- crth2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0412198A GB0412198D0 (en) | 2004-05-29 | 2004-05-29 | Medicinal use of receptor ligands |
GB0414196A GB0414196D0 (en) | 2004-06-24 | 2004-06-24 | Medicinal use of receptor ligands |
GB0424018A GB0424018D0 (en) | 2004-10-29 | 2004-10-29 | Medicinal use of receptor ligands |
PCT/EP2005/005884 WO2005115382A1 (en) | 2004-05-29 | 2005-05-30 | Crth2 receptor ligands for medicinal uses |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1107763A1 true HK1107763A1 (en) | 2008-04-18 |
Family
ID=34993084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07113481.2A HK1107763A1 (en) | 2004-05-29 | 2007-12-11 | Crth2 receptor ligands for medicinal uses |
Country Status (15)
Country | Link |
---|---|
US (2) | US8022063B2 (es) |
EP (2) | EP1758579A1 (es) |
JP (1) | JP2008500991A (es) |
KR (1) | KR20070045153A (es) |
AU (1) | AU2005247110B2 (es) |
BR (1) | BRPI0511676A (es) |
CA (1) | CA2568766A1 (es) |
CR (1) | CR8838A (es) |
EA (1) | EA014729B1 (es) |
HK (1) | HK1107763A1 (es) |
IL (1) | IL179694A (es) |
MX (1) | MXPA06013912A (es) |
NO (1) | NO20066048L (es) |
NZ (1) | NZ551810A (es) |
WO (1) | WO2005115382A1 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0301010D0 (sv) | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
SA04250253B1 (ar) | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
GB0415320D0 (en) | 2004-07-08 | 2004-08-11 | Astrazeneca Ab | Novel compounds |
GB0418830D0 (en) | 2004-08-24 | 2004-09-22 | Astrazeneca Ab | Novel compounds |
GB0422057D0 (en) * | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
DK1817282T3 (da) | 2004-11-23 | 2011-10-10 | Astrazeneca Ab | Til behandling af respiratoriske sygdomme egnede phenoxy derivater |
ES2399061T3 (es) * | 2005-09-30 | 2013-03-25 | Pulmagen Therapeutics (Asthma) Limited | Quinolinas y su uso terapéutico |
US8148572B2 (en) | 2005-10-06 | 2012-04-03 | Astrazeneca Ab | Compounds |
TW200745003A (en) | 2005-10-06 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
WO2007062678A1 (en) * | 2005-11-29 | 2007-06-07 | 7Tm Pharma A/S | Phenoxyacetic acid derivatives as crth2 receptor ligands |
GB0524428D0 (en) * | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
AU2007292993B2 (en) | 2006-09-07 | 2013-01-24 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
ES2400163T3 (es) | 2006-09-08 | 2013-04-08 | Actelion Pharmaceuticals Ltd. | Derivados de piridil-3-ilo como agentes de inmunomodulación |
EP2069318B1 (en) | 2006-09-21 | 2012-09-12 | Actelion Pharmaceuticals Ltd. | Phenyl derivatives and their use as immunomodulators |
EP2079734A1 (en) * | 2006-10-25 | 2009-07-22 | NeuroSearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
TW200848036A (en) | 2006-12-14 | 2008-12-16 | Astellas Pharma Inc | Novel oxycarbonyl compound |
CA2679138C (en) | 2007-03-16 | 2015-05-26 | Actelion Pharmaceuticals Ltd | Amino-pyridine derivatives as s1p1/edg1 receptor agonists |
UA100983C2 (ru) | 2007-07-05 | 2013-02-25 | Астразенека Аб | Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты |
EP2195311B1 (en) | 2007-08-17 | 2011-03-23 | Actelion Pharmaceuticals Ltd. | Pyridine derivatives as s1p1/edg1 receptor modulators |
AU2008306885B2 (en) | 2007-10-04 | 2013-12-05 | Merck Serono S.A. | Oxadiazole derivatives |
KR20100083814A (ko) | 2007-10-04 | 2010-07-22 | 메르크 세로노 에스. 에이. | 옥사디아졸 디아릴 화합물 |
NZ585775A (en) | 2007-11-01 | 2011-12-22 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
AU2008337342B2 (en) | 2007-12-14 | 2012-05-24 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
US9045442B2 (en) * | 2007-12-21 | 2015-06-02 | University Of Notre Dame Du Lac | Antibacterial compounds and methods of using same |
AU2009220893A1 (en) | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
EP2280278A4 (en) | 2008-05-09 | 2015-04-08 | Sysmex Corp | BLOOD ANALYSIS DEVICE, BLOOD ANALYSIS METHOD, AND HEMOLYTIC AGENT |
WO2010006944A1 (en) * | 2008-07-15 | 2010-01-21 | F. Hoffmann-La Roche Ag | Aminotetrahydroindazoloacetic acids |
ATE538100T1 (de) * | 2008-07-15 | 2012-01-15 | Hoffmann La Roche | Aminotetrahydroindazoloessigsäuren |
EP2334666A1 (en) * | 2008-09-08 | 2011-06-22 | Merck Canada Inc. | Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
RU2011130793A (ru) | 2008-12-25 | 2013-01-27 | Тайсо Фармасьютикал, Ко., Лтд. | Изохинолиновое производное |
AU2010212970A1 (en) | 2009-02-12 | 2011-08-18 | Merck Serono S.A. | Phenoxy acetic acid derivatives |
ES2441845T3 (es) | 2009-07-16 | 2014-02-06 | Actelion Pharmaceuticals Ltd. | Derivados de piridin-4-ilo como agonistas de S1P1/EDG1 |
EA201200855A1 (ru) * | 2009-12-23 | 2013-04-30 | Айронвуд Фармасьютикелз, Инк. | Модуляторы crth2 |
EP2586772A4 (en) | 2010-06-23 | 2013-11-13 | Taisho Pharmaceutical Co Ltd | ISOQUINOLINE DERIVATIVE |
BR112013000254A2 (pt) | 2010-07-05 | 2016-05-24 | Actelion Pharmaceuticals Ltd | derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2 |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2665720B1 (en) | 2011-01-19 | 2015-06-10 | Actelion Pharmaceuticals Ltd. | 2-methoxy-pyridin-4-yl derivatives |
KR20140045511A (ko) | 2011-07-29 | 2014-04-16 | 다이쇼 세이야꾸 가부시끼가이샤 | 아미딘 화합물 또는 그의 염 |
BR112014014558A8 (pt) | 2011-12-16 | 2017-07-04 | Atopix Therapeutics Ltd | composição farmacêutica, uso de um antagonista de crth2 e de um inibidor de bomba de prótons, e, kit para o tratamento de esofagite eosinofílica |
BR112014015081A2 (pt) | 2011-12-21 | 2017-06-13 | Actelion Pharmaceuticals Ltd | derivados heterocíclicos e seu uso como moduladores do receptor d2 de prostaglandina |
EP2885307A1 (en) | 2012-07-05 | 2015-06-24 | Actelion Pharmaceuticals Ltd. | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
TWI695831B (zh) | 2014-09-13 | 2020-06-11 | 香港商南北兄弟藥業投資有限公司 | Crth2拮抗劑化合物及其用途 |
WO2016049586A2 (en) | 2014-09-25 | 2016-03-31 | University Of Notre Dame Du Lac | Non-beta lactam antibiotics |
MX2017014846A (es) | 2015-05-20 | 2018-02-19 | Idorsia Pharmaceuticals Ltd | Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi -piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-prop ano-1,2-diol. |
US11168062B2 (en) | 2016-09-12 | 2021-11-09 | University Of Notre Dame Du Lac | Compounds for the treatment of Clostridium difficile infection |
KR102540472B1 (ko) | 2017-08-11 | 2023-06-08 | (주)아모레퍼시픽 | (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물 |
EA202090871A1 (ru) | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | Ингибирование убиквитин-специфической пептидазы 30 |
CA3093802A1 (en) | 2018-03-13 | 2019-09-19 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
EP4218934A1 (en) | 2018-10-05 | 2023-08-02 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 30 (usp30) |
US11370803B2 (en) | 2019-09-18 | 2022-06-28 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
CN114728962A (zh) | 2019-09-18 | 2022-07-08 | 武田药品工业有限公司 | 血浆激肽释放酶抑制剂及其用途 |
JPWO2022138700A1 (es) * | 2020-12-23 | 2022-06-30 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2104932A1 (en) * | 1970-09-08 | 1972-04-28 | Ferlux | O-hydroxyphenyl pyrazoles - hypocholesterolemics anti inflammatories analgesics etc |
RU2142946C1 (ru) * | 1992-12-17 | 1999-12-20 | Пфайзер Инк. | Производные пиразола и фармацевтическая композиция, содержащая их |
AU9002798A (en) | 1997-09-19 | 1999-04-12 | Ono Pharmaceutical Co. Ltd. | Fused or nonfused benzene compounds |
US6291514B1 (en) * | 1998-02-09 | 2001-09-18 | 3-Dimensional Pharmaceuticals, Inc. | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors |
JP3590586B2 (ja) * | 1998-05-05 | 2004-11-17 | エフ.ホフマン−ラ ロシュ アーゲー | P−38mapキナーゼインヒビターとしてのピラゾール誘導体 |
US6316466B1 (en) * | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
US6376527B1 (en) * | 1998-05-05 | 2002-04-23 | Syntex (U.S.A.) Llc | Pyrazole derivatives-p38 map kinase inhibitors |
MXPA02012660A (es) * | 2000-06-20 | 2004-05-14 | Atherogenics Inc | 1,3-(fenilo-substituido-bis)-2-propen-1-onas y su uso para el tratamiento de padecimientos transmitidos por el vcam-1. |
DE60128475T2 (de) * | 2000-07-25 | 2008-02-07 | Merck & Co., Inc. | N-substituierte indole mit anwendung in der behandlung von diabetes |
JP4361798B2 (ja) * | 2001-12-18 | 2009-11-11 | エフ.ホフマン−ラ ロシュ アーゲー | Mdm2インヒビターとしてのシス−イミダゾリン |
SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
WO2003097042A1 (fr) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Antagoniste de recepteur de pdg2 |
EP2423190A1 (en) | 2002-05-16 | 2012-02-29 | Shionogi&Co., Ltd. | Compounds Exhibiting PGD 2 Receptor Antagonism |
GB2388540A (en) | 2002-05-17 | 2003-11-19 | Bayer Ag | New use of Ramatroban |
SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
JP4377815B2 (ja) * | 2002-08-29 | 2009-12-02 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病活性を有するインドール類 |
SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
SA04250253B1 (ar) * | 2003-08-21 | 2009-11-10 | استرازينيكا ايه بي | احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن |
WO2007062678A1 (en) * | 2005-11-29 | 2007-06-07 | 7Tm Pharma A/S | Phenoxyacetic acid derivatives as crth2 receptor ligands |
-
2005
- 2005-05-30 KR KR1020067027504A patent/KR20070045153A/ko not_active Application Discontinuation
- 2005-05-30 CA CA002568766A patent/CA2568766A1/en not_active Abandoned
- 2005-05-30 AU AU2005247110A patent/AU2005247110B2/en not_active Ceased
- 2005-05-30 JP JP2007513846A patent/JP2008500991A/ja not_active Ceased
- 2005-05-30 US US11/597,873 patent/US8022063B2/en not_active Expired - Fee Related
- 2005-05-30 WO PCT/EP2005/005884 patent/WO2005115382A1/en active Application Filing
- 2005-05-30 BR BRPI0511676-7A patent/BRPI0511676A/pt not_active IP Right Cessation
- 2005-05-30 NZ NZ551810A patent/NZ551810A/en unknown
- 2005-05-30 MX MXPA06013912A patent/MXPA06013912A/es not_active Application Discontinuation
- 2005-05-30 EP EP05770220A patent/EP1758579A1/en not_active Withdrawn
- 2005-05-30 EA EA200602290A patent/EA014729B1/ru not_active IP Right Cessation
- 2005-05-30 EP EP10177122A patent/EP2336113A1/en not_active Withdrawn
-
2006
- 2006-11-29 IL IL179694A patent/IL179694A/en not_active IP Right Cessation
- 2006-12-22 CR CR8838A patent/CR8838A/es not_active Application Discontinuation
- 2006-12-28 NO NO20066048A patent/NO20066048L/no not_active Application Discontinuation
-
2007
- 2007-12-11 HK HK07113481.2A patent/HK1107763A1/xx not_active IP Right Cessation
-
2011
- 2011-06-02 US US13/151,317 patent/US20110269763A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA014729B1 (ru) | 2011-02-28 |
NZ551810A (en) | 2010-09-30 |
EA200602290A1 (ru) | 2007-06-29 |
KR20070045153A (ko) | 2007-05-02 |
AU2005247110B2 (en) | 2010-08-26 |
IL179694A0 (en) | 2008-03-20 |
IL179694A (en) | 2012-09-24 |
US8022063B2 (en) | 2011-09-20 |
WO2005115382A1 (en) | 2005-12-08 |
US20090099189A1 (en) | 2009-04-16 |
BRPI0511676A (pt) | 2008-01-08 |
CR8838A (es) | 2009-01-12 |
AU2005247110A1 (en) | 2005-12-08 |
JP2008500991A (ja) | 2008-01-17 |
EP2336113A1 (en) | 2011-06-22 |
EP1758579A1 (en) | 2007-03-07 |
NO20066048L (no) | 2007-02-27 |
CA2568766A1 (en) | 2005-12-08 |
US20110269763A1 (en) | 2011-11-03 |
MXPA06013912A (es) | 2007-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1107763A1 (en) | Crth2 receptor ligands for medicinal uses | |
ZA200703312B (en) | Pharmaceutical compounds | |
HK1155726A1 (en) | Opioid receptor modulators | |
GB0524428D0 (en) | Medicinal use of receptor ligands | |
GB0416728D0 (en) | Medicinal use of receptor ligands | |
IL181229A0 (en) | Noncardiotoxic pharmaceutical compounds | |
GB0414798D0 (en) | Receptor | |
GB0428554D0 (en) | Pharmaceutical compounds | |
GB0424742D0 (en) | Pharmaceutical compounds | |
GB0413872D0 (en) | Receptor | |
GB0424016D0 (en) | Medicinal use of receptor ligands | |
GB0412198D0 (en) | Medicinal use of receptor ligands | |
GB0414195D0 (en) | Medicinal use of receptor ligands | |
GB0414196D0 (en) | Medicinal use of receptor ligands | |
GB0414197D0 (en) | Medicinal use of receptor ligands | |
GB0424015D0 (en) | Medicinal use of receptor ligands | |
GB0414194D0 (en) | Medicinal use of receptor ligands | |
GB0425413D0 (en) | Medicinal use of receptor ligands | |
GB0424018D0 (en) | Medicinal use of receptor ligands | |
AU2004905087A0 (en) | Receptor specific ligands | |
GB0404309D0 (en) | Receptor | |
GB0404584D0 (en) | Receptor | |
GB0413096D0 (en) | Receptor | |
GB0427025D0 (en) | Receptor | |
GB0423327D0 (en) | Receptor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20150530 |